VERV - Verve falls after early-stage data for lead asset
2023-11-13 06:59:53 ET
More on Verve
- Verve's New Beat: CMO Onboard, Catalysts Ahead, But We're Dancing Solo For Now
- Cracking The Cholesterol Code: Verve's High-Stakes Bet
- Verve shares surge to three-month high following Q3 update
- Verve Therapeutics GAAP EPS of -$0.72 beats by $0.20, revenue of $3.12M beats by $2.04M
- Seeking Alpha’s Quant Rating on Verve Therapeutics
For further details see:
Verve falls after early-stage data for lead asset